Table 3.
Imatinib in accelerated phase of chronic myeloid leukemia.
| Study | Patients n° | AP definition | ACA/Ph+ patients | Hematologic response | Cytogenetic/molecular response | Survival |
|---|---|---|---|---|---|---|
| Kantarjian et al. (56) | 200 | IBMTR criteria (modified) | 41% | CHR 80% | MCyR 35% CCyR 24% |
18-mo OS 73% |
| Talpaz et al. (57) | 181 | ELN criteria | excluded | HR 69% | MCyR 24%, CCyR 16% |
1-year PFS 59% 1-year OS 74% |
| Kantarjian et al. (58) | 176 | ELN criteria | 61% (36% with CE only) |
CHR 82% | MCyR 49% CCyR 43% |
4-years OS 53% |
| Palandri et al. (59) | 111 | ELN criteria | 22% | CHR 71% | MCyR 30% CCyR 21% |
7-years PFS 36% 7-years OS 43% |
| Jiang et al. (60) | 87 | WHO criteria | 44% (11% with CE only) |
CHR 85% | MCyR 49%, CCyR 47%, MMR 34% |
6-years PFS 48% 6-years OS 51% |
| Rea et al. (61) | 42 | ELN criteria | 62% (38% with CE only) |
CHR 87% | MCyR 74% CCyR 60% MMR 45% |
2-years PFS 87% 2-years OS 88% |
| Ohanian et al. (62) | 30 | ELN criteria | 33% | CHR 97% | MCyR 83% CCyR 80% MMR 63% |
3-years PFS 96% 3-years OS 87% |
| Furtado et al. (63) | 139 | MDACC criteria | 29% | n.a. | MCyR 55%, CCyR 48% MMR 19% |
5-years OS 66% |
AP, accelerated phase; IBMTR, International Blood and Marrow Transplant Registry; ELN, European LeukemiaNet; WHO, World Health Organization; MDACC, M.D. Anderson Cancer Center; ACA/Ph+, additional chromosome abnormalities in Philadelphia-positive cells; CE, clonal evolution; HR, hematologic response; CHR, complete hematologic response; MCyR, major cytogenetic response; CCyR, complete cytogenetic response; MMR, major molecular response; OS, overall survival; PFS, progression-free survival.